
PROF
Profound Medical Corp.
Company Overview
| Mkt Cap | $184.37M | Price | $6.01 |
| Volume | 64.19K | Change | +2.30% |
| P/E Ratio | -6.6 | Open | $5.93 |
| Revenue | $10.7M | Prev Close | $5.88 |
| Net Income | $-27.8M | 52W Range | $3.76 - $8.75 |
| Div Yield | N/A | Target | $12.31 |
| Overall | 45 | Value | 55 |
| Quality | -- | Technical | 36 |
No chart data available
About Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest News
Lake Street Reaffirms Their Buy Rating on Profound Medical (PRN)
Profound Medical Celebrates Milestone in Incision-Free Prostate Therapy
Profound Medical’s Financial Struggles: Can the Company Secure Funding to Avoid Liquidation?
Stifel Nicolaus Keeps Their Buy Rating on Profound Medical (PRN)
Profound Medical Expands into Saudi Arabia with Exclusive Distribution Agreement
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROF | $6.01 | +2.3% | 64.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |